Falcon Point Capital Lowers stake in BioDelivery Sciences International (BDSI)

BioDelivery Sciences International (BDSI) : Falcon Point Capital reduced its stake in BioDelivery Sciences International by 10.71% during the most recent quarter end. The investment management company now holds a total of 2,200,689 shares of BioDelivery Sciences International which is valued at $5,039,578 after selling 263,855 shares in BioDelivery Sciences International , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.BioDelivery Sciences International makes up approximately 0.85% of Falcon Point Capital’s portfolio.

Other Hedge Funds, Including , Msi Financial Services Inc reduced its stake in BDSI by selling 9 shares or 5.49% in the most recent quarter. The Hedge Fund company now holds 155 shares of BDSI which is valued at $355. First Quadrant L Pca sold out all of its stake in BDSI during the most recent quarter. The investment firm sold 18,700 shares of BDSI which is valued $46,376.Simplex Trading reduced its stake in BDSI by selling 17,412 shares or 92.68% in the most recent quarter. The Hedge Fund company now holds 1,376 shares of BDSI which is valued at $3,412.Cutler Group Lp reduced its stake in BDSI by selling 400 shares or 33.47% in the most recent quarter. The Hedge Fund company now holds 795 shares of BDSI which is valued at $2,059. Searle sold out all of its stake in BDSI during the most recent quarter. The investment firm sold 184,250 shares of BDSI which is valued $477,208.

BioDelivery Sciences International opened for trading at $2.33 and hit $2.6 on the upside on Friday, eventually ending the session at $2.55, with a gain of 8.51% or 0.2 points. The heightened volatility saw the trading volume jump to 15,19,023 shares. Company has a market cap of $137 M.

On the company’s financial health, BioDelivery Sciences International reported $-0.36 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 10, 2016. Analyst had a consensus of $-0.35. The company had revenue of $3.00 million for the quarter, compared to analysts expectations of $2.76 million. The company’s revenue was down -77.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.16 EPS.

Many Wall Street Analysts have commented on BioDelivery Sciences International. Shares were Reiterated by Piper Jaffray on May 12, 2016 to “Overweight” and Lowered the Price Target to $ 4 from a previous price target of $6 .BioDelivery Sciences International was Downgraded by Cantor Fitzgerald to ” Hold” on May 11, 2016. Shares were Reiterated by FBR Capital on May 4, 2016 to “Outperform” and Lowered the Price Target to $ 9 from a previous price target of $12 .

BioDelivery Sciences International Inc. is a specialty pharmaceutical company. The Company develops and commercializes either on its own or in partnerships with third parties applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology a small erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product ONSOLIS (fentanyl buccal soluble film) as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate BELBUCA utilize its BEMA technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *